TESARO (NASDAQ: TSRO) reported Q3 EPS of ($2.49), $0.06 better than the analyst estimate of ($2.55). Revenue for the quarter came in at $64.4 million versus the consensus estimate of $71.76 million.

“In the third quarter, we launched several initiatives to grow the use of ZEJULA for recurrent ovarian cancer and we continued to execute on our development strategies focused on gynecologic and lung cancers as we approach a period of significant data readouts,” said Lonnie Moulder, CEO of TESARO. “Following results of the Phase 3 PRIMA trial next year, we intend for ZEJULA to benefit patients throughout all stages of their ovarian cancer journey, including first-line, recurrent, and late-line treatment settings. Our immuno-oncology pipeline continues to advance, led by our anti-PD-1 antibody, TSR-042, for which we are on track to submit a BLA next year. We look forward to initial data from the Phase 1 AMBER trial of our anti-TIM-3 antibody, TSR-022, in combination with TSR-042, which will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting next week.”

GUIDANCE:

TESARO sees Q4 2018 revenue of $258-265 million, versus the consensus of $258.4 million.

For earnings history and earnings-related data on TESARO (TSRO) click here.